|
online.liebertpub.com/doi/abs/10.1089/scd.2011.0267 Nov 2, 2011 - ... Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies. To cite this article: Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267. Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New TherapiesTo cite this article: Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267 Online Ahead of Print: November 2, 2011 Online Ahead of Editing: September 20, 2011 Published in Volume: 21 Issue 4: September 20, 2011 http://online.liebertpub.com/doi/abs/10.1089/scd.2011.0267 Author informationShengwen Calvin Li,1 Katherine L. Lee,1 and Jane Luo2 1Neuro-Oncology and Stem Cell Research Laboratory, CHOC Children's Hospital Research Institute, University of California Irvine, Orange, California. 2Beckman Coulter, Inc., Brea, California. Address correspondence to: Dr. Shengwen Calvin Li Neuro-Oncology and Stem Cell Research Laboratory CHOC Children's Hospital Research Institute University of California Irvine455 South Main Street Orange, CA 92868 E-mail: shengwel@uci.eduReceived for publication May 26, 2011 Accepted after revision September 20, 2011 ABSTRACTIn contrast to hematological malignancies, meaningful improvements in survival statistics for patients with malignant brain tumors have not been realized in >40 years of clinical research. Clearly, a new medical approach to brain cancers is needed. Recent research has led to a new concept that needs to destroy all cancer subclones to control the cancer progression. However, this new concept fails to distinguish the difference between dominating subclones and dormant subclones. Here, we address the issue of clonal switch and emphasize that there may be one or more than one dominant clones within the tumor mass at any time. Destructing one dominant clone triggers activating other dormant subclones to become dominating subclones, causing cancer progress and post-treatment cancer recurrence. We postulate the concept of subclonal switchboard signaling and the pathway that involved in this process. In the context of stem cell and development, there is a parallel with the concept of quiescent/dormant cancer stem cells (CSC) and their progeny, the differentiated cancer cells; these 2 populations communicate and co-exist. The mechanism with which determines to extend self-renewal and expansion of CSC is needed to elucidate. We suggest eliminating the “dominating subclonal switchboard signals” that shift the dormant subclones to dominating subclones as a new strategy. This paper was cited by:Current achievements and future perspectives of metronomic chemotherapy Adriana Romiti , Rosa Falcone , Michela Roberto , Paolo Marchetti Investigational New Drugs. Jun 2017, Vol. 35, No. 3: 359-374 Crossref Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Nicolas André , Kelvin Tsai , Manon Carré , Eddy Pasquier Trends in Cancer. May 2017, Vol. 3, No. 5: 319-325 Crossref Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors Mayuko Furuta , Masaki Ueno , Akihiro Fujimoto , Shinya Hayami , Satoru Yasukawa , Fumiyoshi Kojima , Koji Arihiro , Yoshiiku Kawakami , Christopher P. Wardell , Yuichi Shiraishi , Hiroko Tanaka , Kaoru Nakano , Kazuhiro Maejima , Aya Sasaki-Oku , Naoki Tokunaga , Keith A. Boroevich , Tetsuo Abe , Hiroshi Aikata , Hideki Ohdan , Kunihito Gotoh , Michiaki Kubo , Tatsuhiko Tsunoda , Satoru Miyano , Kazuaki Chayama , Hiroki Yamaue , Hidewaki Nakagawa Journal of Hepatology. Feb 2017, Vol. 66, No. 2: 363-373 Crossref The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution AiLi Chen , JingYi Yang , ShaoYan Hu , Qian-Fei Wang Science China Life Sciences. Dec 2015, Vol. 58, No. 12: 1302-1305 Crossref Tissue Elasticity Regulated Tumor Gene Expression: Implication for Diagnostic Biomarkers of Primitive Neuroectodermal Tumor Long T. Vu , Vic Keschrumrus , Xi Zhang , Jiang F. Zhong , Qingning Su , Mustafa H. Kabeer , William G. Loudon , Shengwen Calvin Li , Javier S Castresana PLOS ONE. Mar 2015, Vol. 10, No. 3: e0120336 Crossref Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor Shengwen Calvin Li , Lisa May Ling Tachiki , Mustafa H Kabeer , Brent A Dethlefs , Michael J Anthony , William G Loudon Cancer Cell International. Dec 2014, Vol. 14, No. 1 Crossref Metronomics: towards personalized chemotherapy? Nicolas André , Manon Carré , Eddy Pasquier Nature Reviews Clinical Oncology. Jun 2014, Vol. 11, No. 7: 413-431 Crossref Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall Shengwen Li , Long T Vu , Hector W Ho , Hong Yin , Vic Keschrumrus , Qiang Lu , Jun Wang , Heying Zhang , Zhiwei Ma , Alexander Stover , John H Weiss , Philip H Schwartz , William G Loudon Cancer Cell International. Jan 2012, Vol. 12, No. 1: 41 Crossref |
|
|